Who is sponsoring NCT00857259?

NCT00857259 is sponsored by Novartis Pharmaceuticals.

What condition does NCT00857259 study?

NCT00857259 studies Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration.

What drugs are being tested in NCT00857259?

Interventions: Everolimus, Ranibizumab.

What is the status of NCT00857259?

NCT00857259 is currently TERMINATED.

Last reviewed 2011-07-22 · How we verify

A Randomized, Double-masked, Parallel Group Study to Assess the Efficacy of Oral Everolimus, Either Alone or Added to Lucentis, in Patients With Neovascular Age-related Macular Degeneration

NCT00857259 Phase 2 TERMINATED Results posted

The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	TERMINATED
Enrolment	16
Start date	2009-02

Conditions

Choroidal Neo-Vascular Age-onset Macular Degeneration
Age-related Macular Degeneration

Interventions

Everolimus
Ranibizumab

Primary outcomes

Change in Central Retinal Thickness From Baseline to Week 4, as Measured by Optical Coherence Tomography (OCT) — Baseline and 4 weeks
Central retinal thickness was assessed by Optical coherence tomography (OCT). The primary thickness endpoint was the mean thickness of the foveal field of the macula map produced by the analysis of the sequence of six radial scans. Foveal field thickness was the average thickness of a circular field with a diameter of 1 mm. OCT images were analyzed by a central reading center.

Countries

United States, United Kingdom